 Kedrion to acquire, for a total of USD 17M, 2 plasma collection centers and an option to acquire the remaining plasma-derived therapeutic business for USD 5M Liminal to receive up to 70 of net proceeds from sale of Priority Review Voucher for which it is potentially eligible with possible FDA approval for Ryplazim LAVAL, QC and CAMBRIDGE, England, May 17, 2021 PRNewswire - Liminal BioSciences Inc. Nasdaq: LMNL Liminal BioSciences or the Company, a clinical-stage biopharmaceutical company, announced today that the Company has signed a binding Share Purchase Agreement for the sale to Kedrion S.p.A. Kedrion of its plasma collection centers operated in Winnipeg, Manitoba and Amherst, New York, through its subsidiaries, Prometic Plasma Resources Inc., and Prometic Plasma Resources USA Inc. The agreement reflects the recent announcement by Liminal BioSciences to focus its resources on the advancement of the Companys small molecule therapeutics business. 